Glycoprotein IIb/IIIa receptor antagonists inhibit the development of platelet procoagulant activity

Thrombosis Research

Volumn 90, Issue 6, 1998, Pages 247-258

  Pedicord, Donna L ^a   Thomas, Beth E ^a   Mousa, Shaker A ^a   Dicker, Ira B ^a  

^a DUPONT COMPANY   (United States)

Author keywords

Anti platelet agent; c7E3; DMP728; GPIIb IIIa receptor antagonist; Platelet procoagulant activity; Scramblase

Indexed keywords

ABCIXIMAB; CYCLO(DEXTRO 2 AMINOBUTYRYL 2 N METHYLARGINYLGLYCYLASPARTYL 3 AMINOMETHYLBENZOIC ACID) METHANESULFONATE; FIBRINOGEN RECEPTOR ANTAGONIST;

ANTICOAGULATION; ARTICLE; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

BLOOD COAGULATION; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MESYLATES; PEPTIDES, CYCLIC; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, CELL SURFACE; THROMBIN; THROMBOPLASTIN;

EID: 0032526550     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(98)00029-2     Document Type: Article

References (42)

1. Coller B.S., Anderson K., Weisman H.F. New antiplatelet agents. Platelet GP IIb/IIIa antagonists Thromb Haemost. 74(1):1995;302-308.
2. Mousa S., Bennet J.S. Structure and function of platelet GP IIb/IIIa receptors. Serroys P.W., Holmes D. Current Review of Interventional Cardiology. 3:1996;131-140 Current Medicine, Philadelphia, PA.
3. The EPIC Investigators Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330(14):1994;956-961.
4. Moliterno D.J., Califf R.M., Aguirre F.V., Anderson K., Sigmon K.N., Weisman H.F., Topol E.J. Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC trial). Evaluation of c7E3 Fab in the Prevention of Ischemic Complications Trial. Am J Cardiol. 75(8):1995;559-562.
5. Schroit A.J., Zwaal R.F. Transbilayer movement of phospholipids in red cell and platelet membranes. Biochim Biophys Acta. 1071(3):1991;313-329.
6. Sims P.J., Wiedmer T. The response of human platelets to activated components of the complement system. Immunol Today. 12(9):1991;338-342.
7. Zachowski A. Phospholipids in animal eukaryotic membranes. Transverse asymmetry and movement Biochem J. 294(1):1993;1-14.
8. Bevers E.M., Comfurius P., Zwaal R.F. Mechanisms involved in platelet procoagulant response. Adv Exp Med Biol. 344:1993;195-207.
9. Zhou Q., Zhao J., Stout J.G., Luhm R.A., Wiedmer T., Sims P.J. Molecular cloning of human plasma membrane phospholipid scramblase. A protein mediating transbilayer movement of plasma membrane phospholipids. J Biol Chem. 272(29):1997;18240-18244.
10. Bevers E.M., Comfurius P., Zwaal R.F. Changes in membrane phospholipid distribution during platelet activation. Biochim Biophys Acta. 736(1):1983;57-66.
11. Rosing J., Tans G., Govers-Riemslag J.W., Zwaal R.F., Hemker H.C. The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem. 255(1):1980;274-283.
12. van Dieijen G., Tans G., Rosing J., Hemker H.C. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 256(7):1981;3433-3442.
13. Bouchard B.A., Catcher C.S., Thrash B.R., Adida C., Tracy P.B. Effector cell protease receptor-1, a platelet activation-dependent membrane protein, regulates prothrombinase-catalyzed thrombin generation. J Biol Chem. 272(14):1997;9244-9251.
14. Sims P.J., Wiedmer T., Esmon C.T., Weiss H.J., Shattil S.J. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome. An isolated defect in platelet procoagulant activity J Biol Chem. 264(29):1989;17049-17057.
15. Sims P.J., Faioni E.M., Wiedmer T., Shattil S.J. Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. J Biol Chem. 263(34):1988;18205-18212.
16. Comfurius P., Williamson P., Smeets E.F., Schlegel R.A., Bevers E.M., Zwaal R.F. Reconstitution of phospholipid scramblase activity from human blood platelets. Biochemistry. 35(24):1996;7631-7634.
17. Smeets E.F., Comfurius P., Bevers E.M., Zwaal R.F. Calcium-induced transbilayer scrambling of fluorescent phospholipid analogs in platelets and erythrocytes. Biochim Biophys Acta. 1195(2):1994;281-286.
18. Williamson P., Bevers E.M., Smeets E.F., Comfurious P., Schlegel R.A., Zwaal R.F. Continuous analysis of the mechanism of activated transbilayer lipid movement in platelets. Biochemistry. 34(33):1995;10448-10455.
19. Fujimoto T., Fujimura K., Kuramoto A. Electrophysiological evidence that glycoprotein IIb-IIIa complex is involved in calcium channel activation on human platelet plasma membrane. J Biol Chem. 266(25):1991;16370-16375.
20. Frelinger A.L. III, Lam S.C., Plow E.F., Smith M.A., Loftus J.C., Ginsberg M.H. Occupancy of an adhesive glycoprotein receptor modulates expression of antigenic site involved in cell adhesion. J Biol Chem. 273(25):1988;12397-12402.
21. Kouns W.C., Newman P.J., Puckett K.J., Miller A.A., Wall C.D., Fox C.F., Seyer J.M., Jennings L.K. Further characterization of the loop structure of platelet glycoprotein IIIa. Partial mapping of functionally significant glycoprotein IIIa epitopes Blood. 78(12):1991;3215-3223.
22. Gemmell C.H., Sefton M.V., Yeo E.L. Platelet-derived microparticle formation involves glycoprotein IIb-IIIa. Inhibition by RGDS and a Glanzmann's thrombasthenia defect. J Biol Chem. 268(20):1993;14586-14589.
23. Clark E.A., Bruge J.S. Tyrosine Phosphorylation. Watson S.P., Authi K.S. Platelets, A Practical Approach. 1996;199-203 IRL Press, Oxford-New York.
24. Mousa S.A., Bozarth J.M., Forsythe M.S., Jackson S.M., Leamy A., Diemer M.M., Kapil R.P., Knabb R.M., Mayo M.C., Pierce S.K. Antiplatelet and antithrombotic efficacy of DMP 728, a novel platelet GP IIb/IIIa receptor antagonist. Circulation. 89(1):1994;3-12.
25. Mousa SA, Reilly TM. Antiplatelet effects of direct acting thrombin inhibitors and platelet GP IIb/IIIa antagonists: Comparative analysis. Cariovascular Disease: Cellular and Molecular Mechanisms, Prevention, Treatment. Gallo, LL, editor. New York/London: Plenum; 1995. p. 225-67.
26. Mousa SA, Topol E. Recent advances in the development of platelet GP IIb/IIIa receptor antagonists. In: Current Review of International Cardiology, 3rd edition. Serruys PW, Holmes D, editors. Current Medicine: Philadelphia, PA; 1996. p. 13,114-29.
27. Reverter JC, Beguin S, Kessels H, Kumar R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis". J Clin Invest 1996;98(3):863-74.
28. Rosing J., van Rijn J.L., Bevers E.M., van Dieijen G., Comfurius P., Zwaal R.F. The role of activated human platelets in prothrombin and factor X activation. Blood. 65(2):1985;319-332.
29. Miletich J.P., Jackson C.M., Majerus P.W. Interaction of coagulation factor Xa with human platelets. Proc Natl Acad Sci USA. 74(9):1977;4033-4036.
30. Duffy E.J., Lollar P. Intrinsic pathway activation of factor X and its activation peptide-deficient derivative, factor Xdes-143-191. J Biol Chem. 267(11):1992;7821-7827.
31. Barrow R.T., Parker E.T., Krishnaswamy S., Lollar P. Inhibition by heparin of the human blood coagulation intrinsic pathway factor X activator. J Biol Chem. 269(43):1994;26796-26800.
32. van Rijn J., Rosing J., van Dieijen G. Activity of human blood platelets in prothrombin and in factor X activation induced by ionophore A23187. Eur J Biochem. 133(1):1983;1-10.
33. Comfurius P., Senden J.M., Tilly R.H., Schroit A.J., Bevers E.M., Zwaal R.F. Loss of membrane phospholipid asymmetry in platelets and red cells may be associated with calcium-induced shedding of plasma membrane and inhibition of aminophospholipid translocase. Biochim Biophys Acta. 1026(2):1990;153-160.
34. Tilly R.H., Senden J.M., Comfurius P., Bevers E.M., Zwaal R.F. Increased aminophospholipid translocase activity in human platelets during secretion. Biochim Biophys Acta. 1029(1):1990;188-190.
35. Vostal J.G., Jackson W.L., Shulman N.R. Cytosolic and stored calcium antagonistically control tyrosine phosphorylation of specific platelet proteins. J Biol Chem. 266(25):1991;16911-16916.
36. Keenan J.P., Solum N.O. Quantitative studies on the release of platelet fibrinogen by thrombin. Br J Haematol. 23(4):1972;461-466.
37. Thiagarajan P., Tait J.F. Binding of annexin V/placental anticoagulant protein I to platelets. Evidence for phosphatidylserine exposure in the procoagulant response of activated platelets. J Biol Chem. 265(29):1990;7420-7423.
38. Peterson D.M., Stathopoulos N.A., Giorgio T.D., Hellums J.D., Moake J.L. Shear-induced platelet aggregation requires von Willebrand factor and platelet membrane glycoproteins Ib and IIb-IIIa. Blood. 69:1987;625-628.
39. Ikeda Y., Handa M., Kawano K., Kamata T., Murata M., Araki Y., Anbo H., Kawai Y., Watanabe K., Itagaki I. The role of von Willebrand factor and fibrinogen in platelet aggregation under varying shear stress. J Clin Invest. 87(4):1991;1234-1240.
40. Savage B., Shattil S.J., Ruggeri Z.M. Modulation of platelet function through adhesion receptors. A dual role for glycoprotein IIb-IIIa (integrin alpha IIb beta 3) mediated by fibrinogen and glycoprotein Ib-von Willebrand factor. J Biol Chem. 267(16):1992;11300-11306.
41. Swords N.A., Tracy P.B., Mann K.G. Intact platelet membranes, not platelet-released microvesicles, support the procoagulant activity of adherent platelets. Arterioscler Thromb. 13(11):1993;1613-1622.
42. Miyazaki Y., Nomura S., Miyake T., Kagawa H., Kitada C., Taniguchi H., Komiyama Y., Fujimura Y., Ikeda Y., Fukuhara S. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. Blood. 88(9):1996;3456-3464.